• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Synjardy (empagliflozin and metformin hydrochloride)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Synjardy (empagliflozin and metformin hydrochloride)

  • Profile

Profile

Contact Information

Contact: Boehringer Ingelheim Pharmaceuticals Inc.
Website: http://www.synjardy.com/

Currently Enrolling Trials

    Show More

    General Information

    Synjardy is a combination of empagliflozin and metformin, two medicines with complementary mechanisms of action. Empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor, removes excess glucose through the urine by blocking glucose re-absorption in the kidney. Metformin lowers glucose production by the liver and its absorption in the intestine.

    Synjardy is specifically indicated an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing empagliflozin or metformin, or in patients already being treated with both empagliflozin and metformin.

    Mechanism of Action

    Synjardy is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin, a biguanide. Empagliflozin: Sodium-glucose co-transporter 2 (SGLT2) is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Metformin hydrochloride: Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose. It is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike SUs, metformin does not produce hypoglycemia in either patients with type 2 diabetes mellitus or normal subjects (except in special circumstances) and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.

    Side Effects

    Adverse effects associated with the use of Synjardy may include, but are not limited to, the following: 

    Most common adverse reactions associated with empagliflozin:

    • urinary tract infection
    • female genital mycotic infections.

    Most common adverse reactions associated with metformin:

    • diarrhea
    • nausea/vomiting
    • flatulence
    • abdominal discomfort
    • indigestion
    • asthenia
    • headache

    Synjardy comes with a Black Box Warning for the risk of lactic acidosis, a serious metabolic complication that can occur due to metformin accumulation during treatment with Synjardy. The risk increases with conditions such as renal impairment, sepsis, dehydration, excess alcohol intake, hepatic impairment and acute congestive heart failure.

    Dosing/Administration

    Synjardy is supplied as a tablet for oral administration. Synjardy comes in the following dose strengths:

    • 5 mg empagliflozin/500 mg metformin hydrochlorideth
    • 5 mg empagliflozin/1000 mg metformin hydrochloride
    • 12.5 mg empagliflozin/500 mg metformin hydrochloride
    • 12.5 mg empagliflozin/1000 mg metformin hydrochloride

    Individualize the starting dose of Synjardy based on the patient’s current regimen:

    • In patients on metformin, switch to Synjardy containing empagliflozin 5 mg with a similar total daily dose of metformin.
    • In patients on empagliflozin, switch to Synjardy containing metformin 500 mg with a similar total daily dose of empagliflozin.
    • In patients already treated with empagliflozin and metformin, switch to Synjardy containing the same total daily doses of each component.
    • Take Synjardy twice daily with meals with gradual dose escalation to reduce the gastrointestinal side effects due to metformin.
    • In patients with volume depletion not previously treated with empagliflozin, correct this condition before initiating Synjardy.
    • Adjust dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of metformin 2000 mg and empagliflozin 25 mg

    Clinical Trial Results

    There have been no clinical efficacy studies conducted with Synjardy; however, the bioequivalence of Synjardy to empagliflozin and metformin coadministered as individual tablets was demonstrated in healthy subjects. In patients with type 2 diabetes, treatment with empagliflozin and metformin produced clinically and statistically significant improvements in HbA1c compared to placebo. Reductions in HbA1c were observed across subgroups including age, gender, race, and baseline body mass index (BMI). 

     

    Approval Date: 2015-08-01
    Company Name: Boehringer Ingelheim
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing